Results 31 to 40 of about 532,092 (302)

Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer

International Journal of Molecular Sciences, 2014
Neo-angiogenesis is a critical process for tumor growth and invasion and has become a promising target in cancer therapy. This manuscript reviews three currently relevant anti-angiogenic agents targeting the vascular endothelial growth factor system: bevacizumab, ramucirumab and sorafenib. The efficacy of anti-angiogenic drugs in adjuvant therapy or as
Kristensen, Tina Bøgelund, Knutsson, Malin L T, Wehland, Markus, Laursen, Britt Elmedal, Grimm, Daniela Gabriele, Warnke, Elisabeth, Magnusson, Nils E   +6 more
openaire   +3 more sources

Anti-vascular endothelial growth factor therapy for malignant glioma [PDF]

Current Neurology and Neuroscience Reports, 2009
Glioblastomas are among the most vascular tumors because they oversecrete vascular endothelial growth factor (VEGF), a potent stimulator of angiogenesis. Consequently, new drug regimens are being developed to target the VEGF signaling pathway in an attempt to halt tumor growth.
Elizabeth R, Gerstner, A Gregory, Sorensen, Rakesh K, Jain, Tracy T, Batchelor   +3 more
openaire   +2 more sources

Progress in Research on the Role of FGF in the Formation and Treatment of Corneal Neovascularization

Frontiers in Pharmacology, 2020
Corneal neovascularization (CNV) is a sight-threatening disease usually associated with inflammatory, infectious, degenerative, and traumatic disorders of the ocular surface.
Mengji Chen, Licheng Bao, Mengying Zhao, Jiarong Cao, Haihua Zheng   +4 more
doaj   +1 more source

Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells. [PDF]

, 2014
To enable new blood vessel growth, endothelial cells (ECs) express neuropilin 1 (NRP1), and NRP1 associates with the receptor tyrosine kinase VEGFR2 after binding the vascular endothelial growth factor A (VEGF) to enhance arteriogenesis.
Alessandro Fantin, Anastasia Lampropoulou, Anissa Chikh, Anselmi, Ballmer-Hofer, Baruzzi, Birukova, Buchdunger, Campochiaro, Carmeliet, Casanovas, Chen, Chen, Chislock, Cho, Choi, Christiana Ruhrberg, Clark, Claudio Raimondi, Colicelli, Connor, Cui, Cujec, Dejana, Druker, Fantin, Fantin, Fantin, Fantin, Foxton, Fukasawa, Gerhardt, Gerhardt, Herzog, Kawamura, Kawasaki, Kim, Kitsukawa, Koch, Lanahan, Lanahan, Laura Denti, Lewis, Lewis, Mamluk, Murga, Nishijima, Pan, Pan, Parsons, Pasapera, Phng, Raimondi, Ren, Robinson, Roig, Rosenfeld, Ruhrberg, Ruhrberg, Saint-Geniez, Salikhova, Shimizu, Shojaei, Smith, Soker, Sottile, Stenzel, Tvorogov, Uemura, Valdembri, Wang, Welti, Yaqoob, Zaidel-Bar, Zhuang   +74 more
core   +4 more sources

Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone. [PDF]

, 2012
Angiogenesis, the growth of new blood vessels, is necessary for cancerous tumors to keep growing and spreading. Suppression of abnormal angiogenesis may provide therapeutic strategies for the treatment of angiogenesis-dependent disorders.
Belleri M, Ivanova L, Koolwijk P, Mitola S, Mojzis J., Perjesi P, Presta M, van Wijhe M, Varinska L   +8 more
core   +1 more source

Ten years of anti-vascular endothelial growth factor therapy [PDF]

Nature Reviews Drug Discovery, 2016
The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both normal and pathological angiogenesis, has revealed innovative therapeutic approaches in oncology and ophthalmology. The first VEGFA inhibitor, bevacizumab, was approved by the US Food and Drug Administration in 2004 for the first-line treatment of metastatic ...
Ferrara, Napoleone, Adamis, Anthony P
openaire   +4 more sources

Drug treatment of hypertension: focus on vascular health [PDF]

, 2016
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C., Lang, Ninian N., Touyz, Rhian M.   +2 more
core   +1 more source

Lycopene inhibits angiogenesis in human umbilical vein endothelial cells and rat aortic rings [PDF]

, 2011
Angiogenesis is important for tumour vascularisation and growth, and is therefore a promising target for cancer therapy. The present study reports inhibition ofin vitroangiogenesis in human umbilical vein endothelial cells (HUVEC) as well as in rat ...
Chopra, Mridula, Cooper, Alan, Elgass, Simone   +2 more
core   +1 more source

Vascular endothelial growth factor A promotes platelet adhesion to collagen IV and causes early brain injury after subarachnoid hemorrhage

Neural Regeneration Research, 2019
The role of vascular endothelial growth factor A in platelet adhesion in cerebral microvessels in the early stage of subarachnoid hemorrhage remains unclear.
Zun-Wei Liu, Jun-Jie Zhao, Hong-Gang Pang, Jin-Ning Song   +3 more
doaj   +1 more source

Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models. [PDF]

, 2014
The aim of the present study was to examine the efficacy of tumor-targeting Salmonella typhimurium A1-R treatment following anti-vascular endothelial growth factor (VEGF) therapy on VEGF-positive human pancreatic cancer.
Bouvet, Michael, Chishima, Takashi, Endo, Itaru, Hiroshima, Yukihiko, Hoffman, Robert M, Ichikawa, Yasushi, Maawy, Ali, Matsuyama, Ryusei, Miwa, Shinji, Momiyama, Masashi, Mori, Ryutaro, Murakami, Takashi, Sato, Sho, Tanaka, Kuniya, Yamamoto, Mako, Yano, Shuya, Zhang, Yong, Zhao, Ming   +17 more
core   +2 more sources